“Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 2-Year Results from a Phase 3 Study”, J of Skin, vol. 2, no. S1, p. S17, Feb. 2018, doi: 10.25251/skin.2.supp.17.